arrow
E

Emmanuelle Bompas

institut de cancerologie de louest
H指数:60
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

法国去分化脂肪肉瘤的流行病学、人口统计学特征及生存描述性分析

2026-11-030
OAAI
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study

基于法国全国性DEEPSARC研究真实世界数据的非转移性肉瘤辅助化疗经济学评价

2026-06-230
OAAI
A POOLED ANALYSIS OF PHASE 2 CLINICAL TRIALS IN ADVANCED CHORDOMA

晚期脊索瘤II期临床试验的合并分析

2026-06-100
PRE
INST’AJA: a co-designed Instagram campaign to promote sexual health education and behaviors in adolescent and young adult cancer survivors

INST’AJA:一项共同设计的Instagram活动,用于促进青少年和年轻成年癌症幸存者的性健康教育与行为

2026-05-010
PRE
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group

肺泡软组织肉瘤的自然病程和治疗敏感性:法国肉瘤组的全国多中心分析

2026-02-170
OAAI
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

“索拉非尼在局部晚期和转移性脊索瘤患者中的应用: 法国肉瘤组 (GSF/GETO) 的II期试验”

2025-10-150
PRE
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade

转移性骨肉瘤,真实世界国家背景下一十年来患者的治疗模式与结局

2025-09-280
PRE
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database

1773例非皮肤纤维肉瘤浅表肉瘤的结局:一项来自NETSARC数据库的法国肉瘤组(FSG)研究

2025-09-120
PRE
Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

与免疫检查点抑制剂应答相关的临床和生物学因素:晚期肉瘤的IMPRESARC研究——一项法国回顾性多中心队列研究

Cancer
IF5.1
2025-09-050
OAAI
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

恩扎卢替胺联合镭-223治疗转移性去势抵抗性前列腺癌:EORTC 1333/PEACE-3试验结果

2025-05-300
OAAI
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

接受伊马替尼治疗的晚期胃肠道间质瘤的二十年生存率:BFR14试验的探索性长期随访

2025-05-280
OAAI
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma

平滑肌肉瘤中的阿霉素-小梁蛋白和小梁蛋白维持

2024-09-057
PRE
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

LENVAGIST:一项多中心、比较性、安慰剂(P)对照、双盲、II期研究,旨在评估在伊马替尼和舒尼替尼治疗失败的晚期GIST患者中伦伐替尼(L)的疗效。

2024-09-010
PRE
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
2024-09-010
PRE
EREMISS trial: A double-blind placebo (PBO)- controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)

EREMISS试验:一项双盲安慰剂(PBO)对照的随机试验,评估regorafenib(REGO)作为维持疗法在经过一线多柔比星为基础的化疗后的晚期软组织肉瘤(ASTS)患者(pts)中的疗效/安全性。

2024-09-010
PRE